You are here: Industry Insights > PD-L1 Inhibitor News List Maxinovel’s Orally Active PD-L1 Inhibitor Demonstrating Similar Efficacy to PD-L1 Antibody Durvalumab Market news firstwordpharma April 21, 2019 Maxinovel Pharmaceuticals, Inc. presented in the
Cancer immunotherapy and the PD-1/PD-L1 checkpoint …
PD-1 and PD-L1/PD-L2 belong to the family of immune checkpoint proteins that act as co-inhibitory factors that can halt or limit the development of the T cell response. The PD-1/PD-L1 interaction ensures that the immune system is activated only at the appropriate time in order to minimize the possibility of chronic autoimmune inflammation.
Anti-PD-L1 inhibitor durvalumab in bladder cancer
He added that, “these data add to the evidence that blocking PD-1 and PD-L1 is an efficacious way to treat bladder cancer”. Another PD-L1 inhibitor, atezolizumab, was the first-in-class immunotherapy to be approved for bladder cancer by the US Food and Drug Administration, for progression after treatment with platinum, said Emerson Lim (Columbia University Medical Center, New York, NY, USA).
Programmed death ligand-1 (PD-L1) as a predictive …
· Programmed cell death ligand 1 (PD-L1, a transmembrane protein also referred to as CD274 or B7–H1) has emerged as a key biomarker which may predict response to anti-PD1/PD-L1 immune checkpoint inhibitor (ICI) therapy. PD-L1, expressed on tumour cells).
Anti PD-1 and anti PD-L1 Immunotherapies
There seems to be a synergy between Galunisertib, a TGFβ inhibitor (also anti-fibrotic and decreases stem markers), and anti PD-L1 therapy, quoting: Combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition and complete regressions in colon carcinoma models, demonstrating the potential synergy when cotargeting TGFβ and PD-1/PD-L1 pathways.
PD-1 vs PD-L1 Inhibitors: Do Outcomes Differ?
Depending on the type of analyses performed, OS rates were significantly prolonged for patients with NSCLC treated with a PD-1 inhibitor compared with a PD-L1 inhibitor (HR 0.77, 95% CI 0.65-0.92
Roche’s PD-L1 inhibitor Tecentriq approved in China …
Roche has scored approval from China’s National Medical Products Administration for its PD-L1 inhibitor Tecentriq in small cell lung cancer, solidifying its dominance in the setting. The fine print of the approval indicates Tecentriq (atezolizumab) for use in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage SCLC.
Treatment of Immunotherapy Toxicities
· PDF 檔案Blocking binding of PD-1/PD-L1 with a checkpoint inhibitor, cytotoxic T cells are reactivated apoptosis National Cancer Institute 2015 Nat Rev Urol. 2016 July ; 13(7): 420–431. Mechanism of PD-1 and PD-L1 Inhibitors Tumor Ipilimumab Nivolumab Avelumab
BET Bromodomain Inhibition Promotes Anti-tumor …
CD274 (encoding PD-L1) is a direct target of BRD4-mediated gene transcription. In mouse models, treatment with the BET inhibitor JQ1 significantly reduced PD-L1 expression on tumor cells and tumor-associated dendritic cells and macrophages, which
抑制劑篩選試劑盒（Inhibitor Screening Kits）
Inhibition of PD-1-PD-L1 binding by Anti-PD-1 neutralizing antibody (Catalog # PD1-NA001) measured using the PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair (Catalog # EP-101). Product List
Immune Checkpoint Inhibitors
The binding of PD-L1 to PD-1 keeps T cells from killing tumor cells in the body (left panel). Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1) allows the T cells to kill tumor cells (right panel).
PD-1/PD-L1 Inhibitor 2
PD-1/PD-L1 Inhibitor 2 is a novel immunomodulator that prevents the interaction of PD-L1 with PD-1 (IC₅₀ = 18 nM). Target: PD-1 Product Type: Reagent Size: 25 mg Research Area / Disease: Cancer Storage Temperature: ‘-20 C References Kubota, H., et al., J
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 …
· PDF 檔案RESEARCH Open Access CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer Jian Wang1†, Ruiguang Zhang1†, Zhenyu Lin1, Sheng Zhang1, Yaobing Chen2, Jing Tang1, Jiaxin Hong1, Xiaoshu
Pembrolizumab Plus Ipilimumab or Placebo for …
· In the randomized, double-blind, phase III KEYNOTE-598 trial (ClinicalTrials.gov identifier: NCT03302234), eligible patients with previously untreated metastatic NSCLC with PD-L1 TPS ≥ 50% and no sensitizing EGFR or ALK aberrations were randomly allocated 1:1 to ipilimumab 1 mg/kg or placebo every 6 weeks for up to 18 doses; all participants received pembrolizumab 200 mg every 3 weeks for …
Mathematical modeling of an immune checkpoint …
A. Radunskaya, R. Kim and T. Woods II, Mathematical modeling of tumor immune interactions: A closer look at the role of a PD-L1 inhibitor in cancer immunotherapy, Spora: A Journal of Biomathematics, 4 (2018), 25–41, https://ir.library.illinoisstate.edu/cgi.
PD-L1 and similar genes
PD-L1 is similar to these genes: Programmed cell death protein 1, Human leukocyte antigen, Autoimmune regulator and more. The detection of PD-L1 protein seemed to be an indication of cancer susceptible to several immunotherapy medications, but research found that both the lack of this protein or its inclusion in the cancerous tissue was inconclusive, due to the little-understood varying
Downregulation of PD-L1 via FKBP5 by celecoxib …
D’Arrigo et al. 20, 37 demonstrated that targeting of FKBP5 with si-RNA or an inhibitor lowered PD-L1 expression and induced antitumor effects in GBM cells based on in vitro and in vivo studies. Similarly, we found that celecoxib reduced the expression of both